Augmenix's SpaceOAR System can effectively protect the rectum of prostate cancer patients undergoing high dose stereotactic body radiation therapy (SBRT), a new prospective Phase 2 trial shows. The findings were recently reported at the 59th Annual Meeting of the American Society for Radiation Oncology in San Diego, in a presentation titled, “Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer.” “We are excited by the successful results from this study, as it is the first time we’ve evaluated SpaceOAR Hydrogel in prostate cancer patients treated with high-dose SBRT, and the findings confirm a significant clinical benefit,” John Pedersen, CEO of Augmenix, said in a press release. “As this robust data indicates we remain steadfast in our vision to develop disruptive medical technology that improves the lives of patients receiving radiation therapy.” While higher radiation doses are better at killing tumors, the amount of radiation delivered is often limited by the proximity of healthy tissues. In prostate cancer patients, the rectum's proximity is often a problem, as prostate cancer radiation can cause long-term damage to the rectum and other side effects. To overcome this, Augmenix developed a spacer that safely separates the prostate from the rectum.